On June 28, 2016, Biocept, Inc. (the
) held its 2016 Annual Meeting of Stockholders (the
). As of May 11, 2016, the record date for the Annual Meeting, 24,969,975 shares of common stock were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 18,680,378 shares of common stock were present in person or represented by proxy for the two proposals summarized below.
Proposal 1: Election of Directors
The Companys stockholders elected the three persons listed below to serve until the Companys 2019 Annual Meeting of Stockholders. The final voting results are as follows:
David F. Hale
Michael W. Nall
M. Faye Wilson
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm
The Companys stockholders ratified the selection by the Audit Committee of Mayer Hoffman McCann P.C. as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2016. The final voting results are as follows:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 29, 2016
/s/ Michael W. Nall
Michael W. Nall
Chief Executive Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
On February - Feb. 12, 2018
Sabby Healthcare Master Fund, Ltd. just issued a filing suggesting it has sold all of its Biocept - Feb. 1, 2018
On January - Jan. 30, 2018
Biocept just filed a prospectus, suggesting it plans to soon issue some securities - Jan. 26, 2018
Registration adding securities to prior Form S-1 registration [Rule 462(b)] - Jan. 26, 2018